Drugs / RYMPHYSIA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05466747 | Jan 2024 → Apr 2027 | alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease | Takeda | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RYMPHYSIA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05466747 ↗ |
| Modality | Protein / enzyme biologic | “Alpha1-Proteinase Inhibitor (Human)” NCT05466747 ↗ |
| Route | Intravenous | “RYMPHYSIA administered through an IV injection.” NCT05466747 ↗ |